Literature DB >> 7923093

Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.

G Halmos1, J Pinski, B Szoke, A V Schally.   

Abstract

Binding of the radiolabeled bombesin analog [125I-Tyr4]bombesin to crude cell membranes of MKN45 human gastric cancer grown in nude mice was investigated in vitro. Scatchard analyses of multipoint binding data, performed by complete displacement method demonstrated the presence of two classes of [Tyr4]bombesin binding sites. The high-affinity binding sites had a mean dissociation constant (Kd1) of 2.75 nM with a mean maximal binding capacity (Bmax1) of 492 fmol/mg membrane protein, while the low-affinity binding sites showed a mean dissociation constant (Kd2) of 0.41 microM with a mean maximal binding capacity (Bmax2) of 41.4 pmol/mg membrane protein. Binding of [125(1)-Tyr4]bombesin was specific, reversible and linearly related to the protein concentration of tumor membrane. In displacement studies, the binding of radiolabeled [Tyr4]bombesin was inhibited in a dose-dependent manner by gastrin releasing peptide (GRP)(14-27) and two synthetic antagonists of bombesin/GRP, RC-3095 and RC-3950-II. Both antagonists exhibited high affinity in nearly the same concentration range as GRP(14-27). The presence of receptors for bombesin/GRP on human gastric cancer membranes suggests that bombesin-like peptides may play a role in growth of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923093     DOI: 10.1016/0304-3835(94)90246-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Authors:  A Nagy; P Armatis; R Z Cai; K Szepeshazi; G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

2.  Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

Authors:  G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

3.  Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.

Authors:  R Z Cai; H Reile; P Armatis; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  Constitutive activation of the gastrin-releasing peptide receptor expressed by the nonmalignant human colon epithelial cell line NCM460.

Authors:  H A Ferris; R E Carroll; M M Rasenick; R V Benya
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.